Compare Stocks: TNXP, ANNX, DSGN, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.78 -3.0%	$5.40	$2.04 ▼ $7.18	$906.19M	1.21	2.90 million shs	1.44 million shs
DSGN Design Therapeutics	$14.86 -4.3%	$14.05	$5.28 ▼ $17.25	$929.94M	1.66	581,954 shs	241,082 shs
OLMA Olema Pharmaceuticals	$10.66 -1.6%	$11.45	$5.99 ▼ $36.26	$932.75M	1.98	1.38 million shs	404,775 shs
TNXP Tonix Pharmaceuticals	$13.31 -0.5%	$12.08	$9.40 ▼ $31.55	$228.28M	1.74	463,093 shs	225,329 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+0.82%	-1.20%	-6.10%	-9.54%	+138.16%
DSGN Design Therapeutics	+2.58%	-0.38%	+21.71%	+44.47%	+171.03%
OLMA Olema Pharmaceuticals	+2.56%	-0.18%	-3.99%	+1.40%	+67.39%
TNXP Tonix Pharmaceuticals	-4.29%	-1.91%	+25.52%	+12.63%	-51.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.78 -3.0%	$5.40	$2.04 ▼ $7.18	$906.19M	1.21	2.90 million shs	1.44 million shs
DSGN Design Therapeutics	$14.86 -4.3%	$14.05	$5.28 ▼ $17.25	$929.94M	1.66	581,954 shs	241,082 shs
OLMA Olema Pharmaceuticals	$10.66 -1.6%	$11.45	$5.99 ▼ $36.26	$932.75M	1.98	1.38 million shs	404,775 shs
TNXP Tonix Pharmaceuticals	$13.31 -0.5%	$12.08	$9.40 ▼ $31.55	$228.28M	1.74	463,093 shs	225,329 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+0.82%	-1.20%	-6.10%	-9.54%	+138.16%
DSGN Design Therapeutics	+2.58%	-0.38%	+21.71%	+44.47%	+171.03%
OLMA Olema Pharmaceuticals	+2.56%	-0.18%	-3.99%	+1.40%	+67.39%
TNXP Tonix Pharmaceuticals	-4.29%	-1.91%	+25.52%	+12.63%	-51.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	216.80% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	11.04% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	297.75% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	84.07% Upside

Current Analyst Ratings Breakdown

Latest TNXP, ANNX, DSGN, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$4.92 per share	N/A
TNXP Tonix Pharmaceuticals	$29.10M	7.84	N/A	N/A	$12.96 per share	1.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest TNXP, ANNX, DSGN, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
TNXP Tonix Pharmaceuticals	50	17.15 million	16.81 million	Not Optionable

TNXP, ANNX, DSGN, and OLMA Headlines

Recent News About These Companies

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2 at 6:19 PM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2 at 8:14 AM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2 at 7:00 AM | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1 at 4:51 AM | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31 at 9:06 AM | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock

August 24, 2026 | marketbeat.com

Tonix Pharma Names CEO Seth Lederman Interim CMO

August 18, 2026 | tipranks.com

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

August 18, 2026 | marketbeat.com

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

August 17, 2026 | fool.com

Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum

August 12, 2026 | theglobeandmail.com

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

August 11, 2026 | tipranks.com

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

August 10, 2026 | markets.businessinsider.com

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

August 10, 2026 | seekingalpha.com

Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript

August 10, 2026 | finance.yahoo.com

Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?

August 10, 2026 | kalkinemedia.comK

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

August 10, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ANNX, DSGN, and OLMA Company Descriptions

Annexon NASDAQ:ANNX

$4.78 -0.15 (-3.04%)

As of 03:40 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Design Therapeutics NASDAQ:DSGN

$14.86 -0.67 (-4.31%)

As of 03:38 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$10.66 -0.17 (-1.57%)

As of 03:39 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Tonix Pharmaceuticals NASDAQ:TNXP

$13.31 -0.07 (-0.52%)

As of 03:37 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, ANNX, DSGN, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, ANNX, DSGN, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, ANNX, DSGN, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ANNX, DSGN, and OLMA Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, ANNX, DSGN, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, ANNX, DSGN, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, ANNX, DSGN, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ANNX, DSGN, and OLMA Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools